← Eichor
Condition: Thalassemia Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Thalassemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel
Phase N/A · 6 location(s) · Genetix Biotherapeutics Inc. · NCT06271512Effect of Incentive Respiratory Training on Pulmonary Functions and Functional Capacity in Children With B-thalassemia M
NA · 1 location(s) · Rawan Mohammed Khairy Mostafa Elsawy · NCT07112703AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Phase 2 · 1 location(s) · Mitchell Cairo · NCT04099966A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
EARLY_Phase 1 · 1 location(s) · First Affiliated Hospital of Guangxi Medical University · NCT05762510Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease
EARLY_Phase 1 · 1 location(s) · The 923rd Hospital of Joint Logistics Support Force of Peopl · NCT06107400Β-Thalassemia Treatment with KL003 Cell Injection
Phase 1/Phase 2 · 2 location(s) · Kanglin Biotechnology (Hangzhou) Co., Ltd. · NCT06280378Long-term Follow-up Study of BRL-101 for TDT
Phase N/A · 7 location(s) · Bioray Laboratories · NCT06298630A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
Phase 3 · 105 location(s) · Novo Nordisk A/S · NCT06609226A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Particip
Phase 1 · 1 location(s) · First Affiliated Hospital of Guangxi Medical University · NCT05757245Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia
NA · 1 location(s) · Shanghai BDgene Co., Ltd. · NCT05773729A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East
Phase N/A · 2 location(s) · Bristol-Myers Squibb · NCT07215975FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
Phase N/A · 1 location(s) · xCures · NCT06539169A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharma
Phase 2 · 36 location(s) · Bristol-Myers Squibb · NCT05664737RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)
Phase N/A · 1 location(s) · Hospital Universitari Vall d'Hebron Research Institute · NCT06213402Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
Phase 2 · 4 location(s) · New York Medical College · NCT02675959Study of the Role of Genetic Modifiers in Hemoglobinopathies
Phase N/A · 26 location(s) · Cyprus Institute of Neurology and Genetics · NCT05799118A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
Phase 1 · 3 location(s) · Shanghai BDgene Co., Ltd. · NCT06465550In-utero Hematopoietic Stem Cell Transplantation for the Treatment of Fetuses With Bart's Hydrops Fetalis Syndrome
NA · 1 location(s) · Chinese University of Hong Kong · NCT05797272Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
Phase N/A · 2 location(s) · Medical College of Wisconsin · NCT03775954A Long-term Follow-up Study in Participants Who Received CS-101
NA · 1 location(s) · Children's Hospital of Fudan University · NCT06479616Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
Phase N/A · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05991336Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
EARLY_Phase 1 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT06313398A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
Phase 1 · 2 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06772766Transfusion-Related Changes in Oxidative Stress Biomarkers in Neonates
Phase N/A · 1 location(s) · Medical University of Graz · NCT07672275the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
EARLY_Phase 1 · 1 location(s) · Shenzhen Hemogen · NCT05864170A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme
NA · 1 location(s) · Hu Peng · NCT06743477A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or
Phase N/A · 2 location(s) · Bristol-Myers Squibb · NCT06073860Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)
Phase 4 · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT07177300Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
Phase 2 · 26 location(s) · Celgene · NCT04143724A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Tria
Phase 3 · 143 location(s) · Celgene · NCT04064060
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.